Chromosome 3p and breast cancer

AbstractSolid tumors in humans are now believed to develop through a multistep process that activates oncogenes and inactivates tumor suppressor genes. Loss of heterozygosity at chromosomes 3p25, 3p22–24, 3p21.3, 3p21.2–21.3, 3p14.2, 3p14.3, and 3p12 has been reported in breast cancers. Retinoid acid receptor β2 (3p24), thyroid hormone receptor β1 (3p24.3), Ras association domain family 1A (3p21.3), and the fragile histidine triad gene (3p14.2) have been considered as tumor suppressor genes (TSGs) for breast cancers. Epigenetic change may play an important role for the inactivation of these TSGs. Screens for promoter hypermethylation may be able to identify other TSGs in chromosome 3p. Alternatively, use of an “epigenetic modifier” may enhance the response to another type of agent for breast cancer.

[1]  N. Martinet,et al.  Expression of retinoid receptor genes and proteins in non-small-cell lung cancer. , 1999, Journal of the National Cancer Institute.

[2]  J. Minna,et al.  High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss. , 2001, The American journal of pathology.

[3]  P. Devilee,et al.  At least four different chromosomal regions are involved in loss of heterozygosity in human breast carcinoma. , 1989, Genomics.

[4]  A. Tanigami,et al.  Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer. , 1990, Cancer research.

[5]  C. Croce,et al.  The FHIT Gene, Spanning the Chromosome 3p14.2 Fragile Site and Renal Carcinoma–Associated t(3;8) Breakpoint, Is Abnormal in Digestive Tract Cancers , 1996, Cell.

[6]  C. López-Otín,et al.  Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. , 1998, Endocrine reviews.

[7]  M. Widschwendter,et al.  Loss of retinoic acid receptor beta expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer. , 1997, Cancer research.

[8]  B. Agnarsson,et al.  Analysis of the fragile histidine triad (FHIT) gene in lobular breast cancer. , 2000, European journal of cancer.

[9]  B. Ljung,et al.  Molecular aspects of early stages of breast cancer progression , 1993, Journal of cellular biochemistry. Supplement.

[10]  I. Ellis,et al.  High levels of allele loss at the FHIT and ATM genes in non-comedo ductal carcinoma in situ and grade I tubular invasive breast cancers. , 1996, Cancer research.

[11]  Shen-Liang Chen,et al.  Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells , 1999, Molecular carcinogenesis.

[12]  Mi-Ock Lee,et al.  Modulation of retinoic acid sensitivity in lung cancer cells through dynamic balance of orphan receptors nur77 and COUP‐TF and their heterodimerization , 1997, The EMBO journal.

[13]  R. Lidereau,et al.  Presence of two members of c-erbA receptor gene family (c-erbA beta and c-erbA2) in smallest region of somatic homozygosity on chromosome 3p21-p25 in human breast carcinoma. , 1989, Journal of the National Cancer Institute.

[14]  Q. Li,et al.  Recombinant adenovirus expressing Von Hippel-Lindau-mediated cell cycle arrest is associated with the induction of cyclin-dependent kinase inhibitor p27Kip1. , 1998, Biochemical and biophysical research communications.

[15]  G. Hortobagyi,et al.  Progressive decrease in nuclear retinoic acid receptor beta messenger RNA level during breast carcinogenesis. , 1997, Cancer research.

[16]  B. Ljung,et al.  Deletion of two separate regions on chromosome 3p in breast cancers. , 1994, Cancer research.

[17]  K. Umesono,et al.  The nuclear receptor superfamily: The second decade , 1995, Cell.

[18]  R. Bland,et al.  Characterization of thyroid hormone (T3) receptors in three osteosarcoma cell lines of distinct osteoblast phenotype: interactions among T3, vitamin D3, and retinoid signaling. , 1994, Endocrinology.

[19]  S. Lippman,et al.  Expression and up-regulation of retinoic acid receptor-beta is associated with retinoid sensitivity and colony formation in esophageal cancer cell lines. , 1999, Cancer research.

[20]  E. Li,et al.  Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases , 1998, Nature Genetics.

[21]  Klaus Damm,et al.  Protein encoded by v-erbA functions as a thyroid-hormone receptor antagonist , 1989, Nature.

[22]  C. Bain,et al.  Somatic mutations of von Hippel‐Lindau (VHL) tumor‐suppressor gene in european kidney cancers , 1995, International journal of cancer.

[23]  M. Sporn,et al.  N-(4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. , 1979, Cancer research.

[24]  U. Lehmann,et al.  Quantitative assessment of promoter hypermethylation during breast cancer development. , 2002, The American journal of pathology.

[25]  J. Herman,et al.  DNA hypermethylation in tumorigenesis: epigenetics joins genetics. , 2000, Trends in genetics : TIG.

[26]  V. Seewaldt,et al.  Expression of retinoic acid receptor beta mediates retinoic acid-induced growth arrest and apoptosis in breast cancer cells. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[27]  A. Riggs,et al.  DNA methylation and gene function. , 1980, Science.

[28]  D. Sinnett,et al.  DNA methylation of retinoic acid receptor beta in breast cancer and possible therapeutic role of 5-aza-2'-deoxycytidine. , 1999, Anti-cancer drugs.

[29]  Peter A. Jones,et al.  Cancer-epigenetics comes of age , 1999, Nature Genetics.

[30]  L. Shan,et al.  Allelic loss of chromosome 3p24 correlates with tumor progression rather than with retinoic acid receptor β2 expression in breast carcinoma , 2001, Breast Cancer Research and Treatment.

[31]  J. Puymirat,et al.  Overexpression of the beta 1 thyroid receptor induces differentiation in neuro-2a cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Y. Nakamura,et al.  Allelic losses of loci at 3p25.1, 8p22, 13q12, 17p13.3, and 22q13 correlate with postoperative recurrence in breast cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  J. Minna,et al.  Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. , 2002, Cancer research.

[34]  S. Masushige,et al.  Effect of retinoid status on alpha, beta and gamma retinoic acid receptor mRNA levels in various rat tissues. , 1992, The Biochemical journal.

[35]  J. Minna,et al.  The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. , 2000, Cancer research.

[36]  W. Kuo,et al.  Biallelic inactivation of the thyroid hormone receptor beta1 gene in early stage breast cancer. , 2002, Cancer research.

[37]  J. Franklyn,et al.  Thyroid hormone and estrogen receptor expression in normal pituitary and nonfunctioning tumors of the anterior pituitary. , 1997, The Journal of clinical endocrinology and metabolism.

[38]  John Calvin Reed,et al.  Retinoic acid receptor beta mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells , 1996, Molecular and cellular biology.

[39]  G. Canavese,et al.  Biological activity of all-trans-retinoic acid with and without tamoxifen and alpha-interferon 2a in breast cancer patients. , 2000, International journal of oncology.

[40]  M. Emmert-Buck,et al.  Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast. , 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[41]  Y. Pekarsky,et al.  FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. , 1999, Cancer research.

[42]  V. Ingram,et al.  Cloning and sequencing of a cDNA encoding DNA methyltransferase of mouse cells. The carboxyl-terminal domain of the mammalian enzymes is related to bacterial restriction methyltransferases. , 1988, Journal of molecular biology.

[43]  S. Dairkee,et al.  Increased risk of local recurrence is associated with allelic loss in normal lobules of breast cancer patients. , 2002, Cancer research.

[44]  G. Merlo,et al.  Somatic mutations and human breast cancer. A Status Report , 1992, Cancer.

[45]  Bert Vogelstein,et al.  DNMT1 and DNMT3b cooperate to silence genes in human cancer cells , 2002, Nature.

[46]  M. Emi,et al.  Detailed deletion mapping of chromosome arm 3p in breast cancers: A 2‐cM region on 3p14.3‐21.1 and a 5‐cM region on 3p24.3‐25.1 commonly deleted in tumors , 1997, Genes, chromosomes & cancer.

[47]  A. Shoemaker,et al.  Expression of retinoic acid nuclear receptors and tissue transglutaminase is altered in various tissues of rats fed a vitamin A-deficient diet. , 1992, The Journal of nutrition.

[48]  Qifeng Yang,et al.  Biallelic inactivation of retinoic acid receptor beta2 gene by epigenetic change in breast cancer. , 2001, The American journal of pathology.

[49]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[50]  B. Rampy,et al.  The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma , 2000, Cancer.

[51]  J. Franklyn,et al.  Thyroid Receptor a 1 and a 2 Mutations in Nonfunctioning Pituitary Tumors* , 1999 .

[52]  P. Chambon.  A decade of molecular biology of retinoic acid receptors , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[53]  S. Baylin,et al.  Aging and DNA methylation in colorectal mucosa and cancer. , 1998, Cancer research.

[54]  J. Minna,et al.  Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene , 1998, Oncogene.

[55]  J. Minna,et al.  Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours , 2001, Oncogene.

[56]  S. Sukumar,et al.  Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor β2 promoter in breast cancer cells , 2000, Oncogene.

[57]  J. Minna,et al.  Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. , 1997, Cancer research.

[58]  T. Bestor,et al.  The DNA methyltransferases of mammals. , 2000, Human molecular genetics.

[59]  D. Xiao,et al.  Orphan Receptor COUP-TF Is Required for Induction of Retinoic Acid Receptor β, Growth Inhibition, and Apoptosis by Retinoic Acid in Cancer Cells , 2000, Molecular and Cellular Biology.

[60]  Y. Nakamura,et al.  Allelic losses as prognostic markers for breast cancers , 2001, International Journal of Clinical Oncology.

[61]  J. Minna,et al.  5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. , 2001, Cancer research.

[62]  S. Cheng,et al.  Stimulation of proliferation by 3,3',5-triiodo-L-thyronine in poorly differentiated human hepatocarcinoma cells overexpressing beta 1 thyroid hormone receptor. , 1994, Cancer letters.

[63]  M. Widschwendter,et al.  Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. , 2000, Journal of the National Cancer Institute.

[64]  A. Thor,et al.  Loss of Heterozygosity in Normal Tissue Adjacent to Breast Carcinomas , 1996, Science.

[65]  M. Sporn,et al.  Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. , 1999, Journal of the National Cancer Institute.

[66]  S. Minucci,et al.  Methyltransferase Recruitment and DNA Hypermethylation of Target Promoters by an Oncogenic Transcription Factor , 2002, Science.

[67]  K. Kakudo,et al.  Clinicopathological significance of fragile histidine triad transcription protein expression in breast carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[68]  Chun Xing Li,et al.  Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3 , 2000, Nature Genetics.

[69]  J. Minna,et al.  Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. , 2001, Journal of the National Cancer Institute.

[70]  J. T. Forbes,et al.  Growth inhibition by retinol of a human breast carcinoma cell line in vitro and in athymic mice. , 1984, Cancer research.

[71]  G. Kelloff,et al.  Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats. , 1989, Cancer research.

[72]  G. Yang,et al.  Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. , 2001, Cancer research.

[73]  V. Álvarez,et al.  Chromosome 3 p loss of heterozygosity and mutation analysis of the FHIT and â-cat genes in squamous cell carcinoma of the head and neck , 1998 .